New at Switzerland Innovation Park Basel Area: SunRegen
The biopharmaceutical company SunRegen Healthcare develops a therapy for neurodegenerative eye diseases like Optic Atrophy. The two co-founders and managers Dr. Yuhong Dong and Mr. David Guan moved their young startup to the Switzerland Innovation Park Basel Area in Allschwil in January 2019.
Yuhong Dong and David Guan, SunRegen Healthcare
In 2020 they hope to reach the next milestone and move their project from preclinical to clinical stage for their lead compound SBC003. This synthetic molecule is derived from a natural active ingredient that can be found in a medical herb used in the oriental medicine. Yuhong and David plan to test their compound for ALS as another target indication. Further, they want to test SBC003 for other neurological and neuromuscular diseases such as Alzheimer’s, Parkinson’s or Huntington’s disease.
At the Switzerland Innovation Park Basel Area in Allschwil, the co-founders concentrate on developing their business. They are especially happy that they were able to move in and start working right from the beginning, thanks to the furnished office. To host visitors, they appreciate the coffee area that is open to all residents as well as the meeting rooms the Switzerland Innovation Park Basel Area offers. “Even before we could afford an office, the team at the Switzerland Innovation Park was very forthcoming. They are always very friendly – we really enjoy being here.”
SunRegen Healthcare is one of the participants of the first round of the BaseLaunch accelerator. Back in 2017, Yuhong and David reached Phase I of the program, benefitting from customized coaching and funding for three months. Although they were not selected for phase II, they persisted in building their startup. In 2018, they won the BIO-Europe 2018 Startup Slam Competition, held in Copenhagen and gained access to a top-tier mentoring program with industry experts from Johnson & Johnson.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.Read More